Crystalgenomics, Inc.

Lucky Limited

Korea Research Institute of Chemical Technology

Yuyu, Inc.

Joong Myung Cho

Seonggu Ro

Young Woo Park

Im Sook Min

Yong Rae Hong

Jeong Eun Na

Sool Ki Kwon

Hyun Ju Cha

Tae Hee Lee

Dongkyu Shin

Yong Bum Lee

Kyu B Han

Deog Young Choi

Young Lan Hyun

Hong Seob So

Hyun H Chung

Chun Hyung Kim

Jae Young Yang

Jae Pyoung Cho

Joo Ho Kim

Cheol Min Kim

In Soo Kim

Seung Chul Lee

Yong Ho Jung

Hee Jung Jung

Seong Gu Ro

Kook Jin Lim

Dong Kyu Shin

Tae Gyu Lee

Jae Hak Kim

Dong Gyu Shin

Jae-yeon Park

Jin Hwan Kim

Young Ho Jeon

Byung-Ha Kim

Won Jang Jeong

Kyung Joo Lee

Yong Beom Lee

Sung Taek Kim

Tae Ryong Kim

Young-Lan Hyun

Cheol Soon Lee

Cheol Hae Lee

Sik Ii Ahn

Jae-Yeon Park

Sik Il Ahn

The present invention relates to a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof and a method for preparing same, and can improve moisture stability while maintaining the characteristics, such as the efficacy and effective dose, of a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of a derivative thereof. In addition, the present invention can simplify the production and manufacturing process of a formulation by improving hygroscopicity.

Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same

The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.

Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain

The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by absormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.

2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same

The present invention provides a compound selected from the group consisting of a compound of formula (I), pharmaceutically acceptable salts, esters, prodrugs, hydrates, solvates and isomers thereof; a use of the compound for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase, and a use of the compound for the manufacture of a medicament for the treatment, relief or prevention of the diseases; a pharmaceutical composition comprising the compound as an active ingredient; and a method for the treatment, relief or prevention of the diseases using the compound. The inventive compound is useful for the treatment, relief or prevention of diseases caused by abnormal or uncontrolled activation of protein kinase.

The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d) of 3 &#x3bc;m to 9 &#x3bc;m and a 90% volume particle diameter (d) of 10 &#x3bc;m to 50 &#x3bc;m, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.

Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability

2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same

The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.

Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same

A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.

Fab I inhibitor and process for preparing same

Novel compounds having hydroxybenzoimidazole carboxylic amide are useful for inhibiting glycogen synthase kinase 3&#x3b2;(GSK-3&#x3b2;).

Glycogen synthase kinase 3&#x3b2; inhibitor, composition and process for the preparation thereof

The present invention provides polynucleotides derived from cDNA of novel type of hepatitis C virus named Korean type hepatitis C virus (KHCV), polypeptides encoded therein, and antibodies directed against the polypeptides; and also provide diagnostics and vaccines employing any of the above materials as active ingredient(s).

Hepatitis C diagnostics and vaccines

HCV diagnostic agents

Plasmids for the high-level expression of bovine growth hormone in yeast and in E. coli are described, as are processes for the production of bovine growth hormone which utilize host cells transformed with the expression vectors.

Method for production of bovine growth hormone using a synthetic gene

High protein content feed or hormonal steroids have been added to fish feed in order to elevate the efficiency of the feed. However, the steroids remain in the fish and may be detrimental to those who eat the fish. The invention relates to a method for the production of salmon growth hormone, which enhances the efficiency of the feed without the above side effects, using a synthetic gene in yeast or E. coli. It has been found that salmon growth hormone may be produced economically and in bulk in yeast or E. coli by gene manipulation technology.

Method for the production of salmon growth hormone using a synthetic gene

Growing community of inventors

Seoul, South Korea

Joong Myung Cho